^
Association details:
| Biomarker: | AXL expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Published date:
10/01/2018
Excerpt:
Pts received a first line treatment according to RAS status:...RAS WT pts (n = 102) CT + cetuximab….In RAS WT cohort, AXL positive pts had a significantly worse median PFS [4.3 m (CI95% 3.2-5.5) vs 12.1 m (CI95% 11.0-13.3) p = 0.001],...
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1093/annonc/mdy269.094
Trial ID:
